Finasteride is a prescription-only medicine that may be prescribed for androgenetic alopecia (male pattern hair loss) in some adults following clinical assessment. It works by reducing dihydrotestosterone (DHT), a hormone involved in follicle miniaturisation in genetically susceptible individuals. Evidence from clinical studies suggests outcomes vary between individuals, and treatment decisions should be made with a qualified healthcare professional.
Androgenetic alopecia is usually managed in UK practice using a range of approaches depending on pattern, severity, and goals. A clinician may discuss licensed options, non-medicine measures, and whether further assessment is needed to exclude other causes of hair shedding.
Male pattern hair loss can be managed in several ways. Options may include topical minoxidil, clinician-led discussion of prescription treatments where appropriate, low-level laser therapy (evidence varies), hair restoration surgery for selected candidates, and non-treatment approaches such as styling or camouflage. The most appropriate plan depends on individual factors reviewed during clinical assessment.
What Is Finasteride and Why Is It Used in Male Pattern Hair Loss?
Finasteride is an oral medicine that decreases dihydrotestosterone (DHT), a hormone that causes hair follicles to shrink in men who are genetically predisposed to it, leading to ongoing thinning. Finasteride is a type 2 5-alpha-reductase inhibitor that blocks the enzyme that converts testosterone into DHT. Lowering DHT may slow follicle miniaturisation and, in some cases, be associated with changes in hair count or density over time.
In placebo-controlled clinical research led by Kaufman (Merck Research Laboratories, USA, et al.), outcomes were assessed using hair-count measures within a defined scalp area over follow-up. In that study setting, the finasteride group was reported to have higher hair-count measures at 1–2 years than placebo. These findings are study-specific and do not predict individual response; in UK practice, prescribing decisions remain clinician-led and based on current UK prescribing information and individual assessment.
Overall, studies suggest finasteride may slow progression in some people, with results varying by individual and by study design.
How Effective Is Finasteride for Hair Loss?
Clinical studies suggest finasteride may slow the progression of male pattern hair loss in some participants. Reported outcomes vary, and results depend on factors such as baseline hair loss, age, and study duration.
A long-term extension study reported by Shapiro (University of British Columbia/Vancouver General Hospital, Canada, et al.) followed participants over several years and reported outcomes using clinical assessments and/or study-defined measures. In that study population, outcomes suggested maintained effects for some participants over time compared with placebo during the controlled phase. Long-term extension findings are context only and do not predict individual response; suitability and follow-up remain prescriber-led in UK practice.
Some studies report better outcomes in participants with earlier-stage hair loss and in younger age groups, although individual responses vary. Some older participants and those with more advanced hair loss may experience less noticeable improvement, although individual responses vary.
In studies where benefits were observed, ongoing use was typically required to maintain those effects. Decisions about duration should be clinician-led.
How Does It Compare to Dutasteride?
Finasteride and dutasteride inhibit 5-alpha reductase, but they are not interchangeable and have different licensing and prescribing considerations in the UK. Comparative studies exist, but interpretation depends on the population studied, duration, and outcome measures. The most appropriate option, if any, should be determined by a qualified healthcare professional.
Studies mentioned below are included for general evidence context and do not indicate suitability for an individual; UK prescribing decisions remain clinician-led and based on current UK prescribing information.
A review/meta-analysis (Gupta, Mediprobe Research Inc, London, et al.) pooled short follow-up studies comparing finasteride and dutasteride using study-defined outcome measures. Some pooled analyses reported differences in selected measures, but conclusions depend on included trials, outcome definitions, and variation between studies.
This evidence is provided for research context only and should not be framed as a reason to request a specific prescription-only medicine; UK prescribing decisions remain clinician-led.
Prescribing and Monitoring Considerations
Finasteride is prescription-only and should be used only under a clinician's supervision. Prescribers consider medical history, contraindications, potential adverse effects, and the need for review during treatment.
According to a pharmacokinetic study conducted by Dr J. Steiner at the University of Wyoming, USA, finasteride absorption was not meaningfully affected by food intake. Pharmacokinetic findings can help explain how the medicine is processed, but prescribing instructions, duration of treatment, and monitoring should be determined by a qualified healthcare professional.
Patient Information Sources
According to NHS patient guidance, missed-dose advice for finasteride is available in official patient information resources. This page does not provide administration instructions.
Who Can Use Finasteride for Hair Loss?
Finasteride is used in adult men with male pattern baldness. It is not usually used in women who are pregnant or may become pregnant because of the risk of harm to foetal development.
Dr Yanagisawa (Kitasato University School of Medicine, Japan, et al.) reported findings from long-term administration in a Japanese study population, including reporting of adverse effects over follow-up. In that study setting, adverse effects were described as infrequent, though sexual adverse effects were reported in some participants. Findings are study-specific and do not predict individual risk; adverse-effect discussions in the UK should follow current UK prescribing information and clinician-led assessment.
Use in women, particularly during pregnancy, raises specific safety concerns and requires specialist clinical judgement. Suitability should be assessed by a qualified healthcare professional.
Finasteride for Women: Is It Prescribed in the UK?
Finasteride is not routinely prescribed for female pattern hair loss in the UK, and use, if considered at all, typically involves specialist oversight. While some experts may prescribe it off-label to postmenopausal women with androgenetic alopecia, or female pattern hair loss (FPHL), these instances are extremely uncommon. FPHL is seen in almost 50% of women throughout their lifetimes, with diffuse thinning at the crown, without the frontal hairline being affected, making it a growing concern in women's health.
This study is included for general evidence context and does not indicate suitability for an individual; UK prescribing decisions remain clinician-led and based on current UK prescribing information.
Topical minoxidil is now the only widely accepted treatment for FPHL, but its efficacy is variable. According to Wimolsiri Iamsumang of the Faculty of Medicine, Ramathibodi Hospital, Thailand, et al., finasteride can have some effect, but its use is limited by safety concerns, such as the risk of foetal damage if taken during pregnancy.
Potential Side Effects of Finasteride
Finasteride can cause adverse effects, and the risk varies between individuals. Reported rates of sexual adverse effects (including decreased libido, erectile dysfunction, and ejaculatory disorders) vary across studies; symptoms may resolve in some individuals, while persistent effects have also been reported.
According to MHRA safety notices, severe but infrequent effects, like depression and suicidal thoughts, have led to the distribution of patient alert cards in the UK. Lingering sexual symptoms, post-finasteride syndrome, have also accompanied long-term therapy, although this is controversial.
According to Venkataram Mysore, Consultant Dermatologist- Hair Transplant Surgeon, Venkat Charmalaya-Centre for Advanced Dermatology, India, some of the commonly faced questions by a physician while treating a patient of pattern hair loss are about the possible sexual side effects caused by finasteride. Even dermatologists seem to hesitate to prescribe the medicine on a long-term basis.
Potential benefits and risks should be discussed with a qualified healthcare professional.
Supplements and Supportive Measures
Supplements are not usually required for finasteride to have its intended effect, but nutritional status may still be relevant when assessing hair health. However, personalised vitamins or hair-nourishing nutrients such as biotin, zinc, or vitamin D can be prescribed by dermatologists if nutrition is insufficient, though none of these enhances the medicine's effect.
According to Dr Emily L Guo from the Baylor College of Medicine, USA, et al., supplements like biotin, vitamin D, or zinc may support general hair health if dietary intake is insufficient, but they cannot replace finasteride's DHT-blocking effect. Some herbal products may affect hormone-related pathways, so any supplement use should be discussed with a qualified healthcare professional.
Some supplements are used to address nutritional deficiencies, but evidence for their effectiveness in improving outcomes in androgenetic alopecia is mixed. Any supplement use should be discussed with a healthcare professional, particularly where there are underlying conditions or concurrent medicines.
Time to Respond in Clinical Studies
Some men may notice reduced shedding after several months, with any improvement developing gradually. In some individuals, reduced shedding may be an early sign of response, but changes vary and should be reviewed over time with a clinician. Any changes in hair density or coverage, where they occur, are typically gradual and may be easier to assess after several months of clinician-supervised use. Most men continue to notice improvement if they maintain the treatment for a couple of years.
In placebo-controlled clinical research led by Kaufman (Merck Research Laboratories, USA, et al.), hair-count outcomes were assessed within a defined scalp area over follow-up. In that study setting, hair-count measures were reported to be higher in the finasteride group than in the placebo group at 1–2 years. These findings are study-specific and do not predict individual response; timing and degree of change vary and should be reviewed with a prescriber.
If treatment is stopped, published studies and clinical discussions describe a gradual return towards baseline patterns over time, although timing varies and should be reviewed with a clinician. If the response is inadequate or adverse effects occur, a clinician may review ongoing suitability and discuss alternatives.
Prescribing and Regulatory Considerations in the UK
Finasteride is a prescription-only medicine in the UK. Any use should be assessed by an appropriate prescriber and dispensed through regulated UK pharmacy channels. Access arrangements may vary by provider, and prescribing decisions should remain clinician-led.
For male pattern hair loss, finasteride is generally obtained on a private prescription in the UK rather than through NHS prescribing. Information on prescribing status and patient guidance should be checked against current NHS and UK regulatory sources.
Long-Term Use: Evidence and Monitoring
Long-term data exist, but ongoing review is important because adverse effects can occur, and reporting varies between studies. Clinicians typically consider individual risk factors and review symptoms over time. However, data from BPH trials did not systematically monitor liver or metabolic effects, so long-term safety in users for hair loss is an evolving picture.
This study is included for general evidence context and does not indicate suitability for an individual; UK prescribing decisions remain clinician-led and based on current UK prescribing information.
According to Oliveira-Soares from the Hospital Cuf Torres Vedras, Portugal, et al., observational data suggest a modest increase in new-onset type 2 diabetes with long-term 5-alpha-reductase inhibitor use versus tamsulosin. Clinicians should monitor metabolic health during prolonged therapy.
UK regulators also state psychiatric and sexual side effects, and now add a finasteride patient alert card to enable earlier symptom detection and reporting. If treatment is stopped, published studies and clinical discussions describe a gradual return towards baseline patterns over time, although timing varies and should be reviewed with a prescriber.
Final Thoughts
Finasteride is a prescription-only medicine that may be prescribed for male pattern hair loss in selected adults after clinical assessment. Evidence from clinical studies suggests potential benefit for some individuals, but outcomes vary, and adverse effects can occur. Treatment decisions and follow-up should be led by a qualified healthcare professional.
Finasteride is not an immediate treatment, and any benefits reported in clinical studies are typically associated with ongoing clinician-supervised use. Potential benefits should be considered alongside possible adverse effects, and suitability should be assessed by a qualified healthcare professional.
A clinician may review whether the current formulation remains appropriate as part of ongoing treatment decisions.